Table 2 Laboratory, radiologic and microbiological findings
From: Xanthogranulomatous pyelonephritis: a focus on microbiological and antibiotic resistance profiles
Variable | Value (n and %) |
|---|---|
Laboratory | |
Urine sediment | |
Pyuria, n (%) | 7 (25.9%) |
Microscopic hematuria, n (%) | 3 (11.1%) |
Blood tests | |
Hemoglobin in g/dL, mean (SD) | 10.1 (SD 1.5) |
Serum creatinine in mg/dL, mean (SD) | 1.5 (SD 1.2) |
Estimated GFR in mL/min, mean (SD) | 62.01 (SD 27.39) |
WBC count per microliter, mean (SD) | 12,508.1 (SD 4350.1) |
CT findings (M&E classification) | |
Malek 1 | 10 (37%) |
Malek 2 | 8 (29.6%) |
Malek 3 | 8 (29.6%) |
Psoas abscess | 3 (11.1%) |
Positive urine culture | 13 (48.1%) |
Proteus mirabilis | 5 (18.5%) |
Escherichia coli | 4 (14.8%) |
Pseudomonas aeruginosa | 2 (7.4%) |
Mixed | |
E. coli + Streptococcus constellatus | 1 (3.7%) |
P. mirabilis + Serratia marcescens | 1 (3.7%) |
Prescribed antibiotics | |
Piperacillin/tazobactam (TZP) | 13 (48.1%) |
Ceftriaxone | 5 (18.5%) |
Amoxicillin/clavulanic acid | 3 (11.1%) |
Others | 6 (21.9%) |
Overall antibiotic resistance profile (%) | |
Quinolones | 14.30% |
Carbapenems | 0% |
Amoxicillin/clavulanic acid | 12.50% |
Piperacillin/tazobactam (TZP) | 14.30% |
Ceftriaxone | 16.60% |
Fosfomycin | 33.30% |
Trimethoprim/sulfamethoxazole (TMP/SMX) | 33.30% |